Literature DB >> 17216252

Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy.

M Colleen Hastings1, Robert J Wyatt, Bettina H Ault, Deborah P Jones, Keith K Lau, A Osama Gaber, Lillian W Gaber.   

Abstract

Thrombotic microangiopathy has been reported in association with calcineurin inhibitors and less frequently with sirolimus in renal transplant patients. The diagnosis of thrombotic microangiopathy is typically made by diagnostic biopsy in the setting of allograft dysfunction. The finding of thrombotic microangiopathy on surveillance biopsy without a significant elevation of baseline serum creatinine is unusual. The optimal treatment of this disorder remains controversial. Treatment strategies have included dose adjustment, drug substitution, plasmapheresis, and intravenous immunoglobulin G. We report a case of de novo thrombotic microangiopathy diagnosed by surveillance biopsy in a patient without hematologic abnormalities or elevated serum creatinine. This patient had resolution of the renal lesion following conversion from tacrolimus to sirolimus-based immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216252     DOI: 10.1007/s00467-006-0392-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

Review 1.  Haemolytic-uraemic syndrome: basic science.

Authors:  J L Moake
Journal:  Lancet       Date:  1994-02-12       Impact factor: 79.321

2.  Cyclosporine and tacrolimus-associated thrombotic microangiopathy.

Authors:  P T Pham; A Peng; A H Wilkinson; H A Gritsch; C Lassman; P C Pham; G M Danovitch
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

3.  De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.

Authors:  J Waiser; K Budde; B Rudolph; M A Ortner; H H Neumayer
Journal:  Am J Kidney Dis       Date:  1999-09       Impact factor: 8.860

4.  Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen.

Authors:  Sander Florman; Corinne Benchimol; Kenneth Lieberman; Lewis Burrows; Jonathan S Bromberg
Journal:  Pediatr Transplant       Date:  2002-08

5.  De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus.

Authors:  A Franco; D Hernandez; L Capdevilla; P Errasti; M Gonzalez; J C Ruiz; J Sanchez
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

Review 6.  Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management.

Authors:  A Agarwal; S M Mauer; A J Matas; K A Nath
Journal:  J Am Soc Nephrol       Date:  1995-10       Impact factor: 10.121

Review 7.  De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.

Authors:  Joshua Schwimmer; Tibor A Nadasdy; Patrice F Spitalnik; Karen L Kaplan; Martin S Zand
Journal:  Am J Kidney Dis       Date:  2003-02       Impact factor: 8.860

8.  Conversion to sirolimus in solid organ transplantation: a single-center experience.

Authors:  M F Egidi; P A Cowan; A Naseer; A O Gaber
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

9.  Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.

Authors:  Aimee K Sundberg; Michael S Rohr; Erica L Hartmann; Patricia L Adams; Robert J Stratta
Journal:  Clin Transplant       Date:  2004       Impact factor: 2.863

10.  Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy.

Authors:  F M Jeejeebhoy; J S Zaltzman
Journal:  Transplantation       Date:  1998-06-27       Impact factor: 4.939

View more
  2 in total

Review 1.  New insights into postrenal transplant hemolytic uremic syndrome.

Authors:  Julien Zuber; Moglie Le Quintrec; Rebecca Sberro-Soussan; Chantal Loirat; Véronique Frémeaux-Bacchi; Christophe Legendre
Journal:  Nat Rev Nephrol       Date:  2010-11-23       Impact factor: 28.314

2.  A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study.

Authors:  Tao Zhang; Huimei Chen; Shaoshan Liang; Dacheng Chen; Chunxia Zheng; Caihong Zeng; Haitao Zhang; Zhihong Liu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.